ACCELERATING (PRE)CLINICAL DEVELOPMENT

The TIM technology was introduced 30 years ago and has been further developed, currently representing the most advanced dynamic in vitro GI model available.

By employing a proprietary in vitro technology called TIM, TIM Studies have changed what’s possible with accurate predictions of the bioaccessibility of oral drug or food candidates.

“Multiple candidate formulations can be tested in a relative short period of time at a fraction of the cost of a clinical study”  – Pfizer

Scientists now have alternatives to relying solely on animal studies or traditional dynamic dissolution methods, which typically show moderate in vitro-in vivo correlations of around ~.5

TIM Studies exceed in predicting in vivo behaviour of novel formulations and drug products during transit in the gastrointestinal tract, with ~.9 In vitro-in vivo correlations.

TIM accurately explains the fate of the oral drug while travelling through the GI tract.

Our studies determine the fraction available for absorption (bioaccessible), luminal concentrations and the non-bioaccessible fraction.

The mechanics that make this possible include exact mimicking of the physiological transit times between GI segments, motility, pressure and shear forces, secretions, temperature control and local pH values.

TIM data can be combined with intestinal tissue explants or in silico models (i.e. Gastro+,Simcyp) for further drug performance assessment and blood plasma levels.